Amrize Cuts 2026 Outlook as Roofing Recovery Slips to 2027
Published on 10/30/2026 at 14:41 | Editorial boerse-global.de
Amrize has trimmed its full-year targets, and the timing of the revision matters as much as the revision itself. The building materials group now expects 2026 revenue of USD 12.2bn to 12.4bn, with adjusted EBITDA of USD 2.95bn to 3.05bn — figures that landed alongside a Morningstar analysis published today. The midpoint of the sales range drops 2.4%, while the midpoint of the earnings range falls 4.8%, a steeper cut that suggests pricing alone cannot neutralize the company's cost pressures.
That asymmetry is the heart of the story. Amrize, spun out of Holcim's North American operations in 2025, operates through two divisions — Building Materials and Building Envelope — and they are currently pulling in opposite directions.
Two divisions, two verdicts
In Building Materials, the numbers read like a textbook case of pricing power. Cement prices rose 1.8% in the third quarter and aggregate prices climbed 6.9%, even as cement volumes fell 4.2%. The segment's margin improved 30 basis points, with pricing and acquisitions offsetting weather-related volume declines — a performance detailed at yesterday's earnings conference.
Building Envelope tells a different story. Adjusted EBITDA there dropped 14.6%, and management now expects a positive net balance from pricing and costs only in 2027. For investors, that distinction carries more weight than any single revenue line: defending prices is not the same as growing volumes, and a solid price list can coexist with pressure further down the income statement.
Should investors sell immediately? Or is it worth buying Amrize?
The quarterly counterweight
The third quarter itself offered some ballast. Amrize posted USD 3.77bn in revenue and adjusted earnings per share of USD 1.05, according to Morningstar's analysis. Those figures argue against any blanket crisis narrative — a respectable quarter and a weaker outlook can stand side by side.
The share price reaction added another layer. The stock gained 10% yesterday, a move that says more about sentiment than about the underlying business. A single session's rally is no proof that an operational turnaround has taken hold, and it would be premature to read the jump as an all-clear.
Cost discipline, with limits
Amrize is pushing back against the headwinds with internal measures. The ASPIRE savings program has delivered USD 73m since the start of the year against a full-year target of USD 80m, with the company aiming for USD 250m by 2028. A substantial share of this year's goal is already banked — a genuine execution signal.
Still, savings can support earnings without reviving demand. They are no substitute for the delayed improvement at Building Envelope, and the two facts can hold true at once: costs come down while the operating recovery keeps slipping.
Capital returns and the wider sector
Shareholder payouts are tangible but answer none of the operational questions. Amrize completed its USD 1bn buyback program on Wednesday and declared a quarterly dividend of USD 0.11 per share, payable on 18 November. Neither move improves the price-cost trajectory nor lifts the lowered annual targets.
Amrize at a turning point? This analysis reveals what investors need to know now.
The weakness is not Amrize's alone. CRH also cut its profit guidance yesterday, with revenue and adjusted EBITDA both declining in its Americas Building Solutions unit. CRH now expects adjusted EBITDA of USD 7.8bn to 8.0bn, against Amrize's USD 2.95bn to 3.05bn. What links the two is the direction of the revisions, not their scale — and that shared direction does not prove identical causes. At Amrize, weather-related volume losses and cost pressure in roofing are explicitly part of the picture, so lumping every building materials company under one weak-housing headline misses the differences that matter.
The test ahead is narrower than a macro call. Can Amrize's defended prices flow through to earnings once volumes and costs are accounted for? That, rather than the size of its buybacks, is what the coming quarters will settle.
Ad
Amrize Stock: New Analysis - 30 October
Fresh Amrize information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
